Gyre Therapeutics, Inc. (GYRE) Q3 2026 earnings results
Gyre Therapeutics, Inc. (GYRE) reported Q3 2026 results on Nov 5, 2026, 4:30:20 PM ET: GAAP EPS -$0.04 vs. -$0.12 expected (beat by 65.7%); revenue $32.93M vs. $28.40M expected (beat by 16.0%). Outlook: Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.04 | -$0.12 | Beat by 65.7% |
| Revenue | $32.93M | $28.40M | Beat by 16.0% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:30:20 PM ET. Nexqual published them 101 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 0.7% from $32.69M; GAAP diluted EPS was -$0.04 vs. $0.01.
Stock reaction
The results came out after the market closed. GYRE closed at $4.76 on November 6, 2026, up 18.7% from its $4.01 close on November 5, 2026 before the results. Latest: $4.30 as of 11:40 AM ET, +7.1% since the pre-release close.
Questions and answers
Did Gyre Therapeutics, Inc. beat earnings expectations?
Yes. Gyre Therapeutics, Inc. reported GAAP EPS of -$0.04 against an average analyst estimate of -$0.12 (beat by 65.7%), and revenue of $32.93M against $28.40M expected (beat by 16.0%).
What were Gyre Therapeutics, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.04 and revenue of $32.93M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 0.7% from $32.69M; GAAP diluted EPS was -$0.04 vs. $0.01.
When did Gyre Therapeutics, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:30:20 PM ET, in an SEC 8-K filing (Item 2.02).
How did GYRE stock react to the earnings?
The results came out after the market closed. GYRE closed at $4.76 on November 6, 2026, up 18.7% from its $4.01 close on November 5, 2026 before the results. Latest: $4.30 as of 11:40 AM ET, +7.1% since the pre-release close.
What did Gyre Therapeutics, Inc. say about its outlook?
Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed.
More on GYRE
GYRE stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt